Abstract B cells were previously shown to mediate partial protection against CMV infection, as in the absence of B cells, latently infected mice were more susceptible to virus reactivation. It remains unclear if this eVect stems from the loss of B cells as antibody producers or as antigen presenting cells. To address this fundamental question, we propose to make use of new mouse models that allow conditional ablation of B cells or that allow for the generation of mice with B cells that are not able to produce antibodies.
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Short history of B cells and CMV infection
Cytomegaloviruses (CMVs) are members of the herpesvirus family. CMVs show host species-speciWcity; for instance, human CMV (HCMV) and murine CMV (MCMV) infect humans and mice, respectively. Primary infection with HCMV or MCMV is controlled by the immune system and in particular cytotoxic T cells (CTLs) were shown to play a critical role (for a review see [1] ). Like the other members of the herpesvirus family, CMVs cannot be entirely eliminated by the infected host, even if the immune system is intact. After the primary infection is controlled, CMVs remain in reservoirs in a state of latency. The cell types in which the virus persists are yet to be identiWed. In humans as well as in mice, reactivation of latent CMV can occur when the host is immunosuppressed. In immunocompromised or immunosuppressed patients, CMV reactivation can result in invasive CMV disease such as pneumonitis, esophagitis, encephalitis, hepatitis, pancreatitis, adrenalitis, gastritis, enteritis, colitis, and retinitis [2, 3] . HCMV is by far the most common infection in solid organ transplant recipients, with over half of the patients showing evidence of active infection (viral replication). In addition to the debilitating eVects of direct, organ-speciWc syndromes such as bilateral interstitial pneumonia, disseminated CMV disease is widely believed to cause graft injury and shorten graft survival [4, 5] . Much is known about the factors that control the primary CMV infection, but much less is known about how to control the reactivation of the virus, or in fact which cellular and humoral factors keep the virus inactive after the Wrst infection is resolved.
Antibodies were found to have a protective role in mice infected with MCMV [6] . CMV-speciWc serum was administered to infected mice and was shown to partially protect the mice [7] . These results were conWrmed by experiments where serum from infected C57BL/6 mice, but not naïve mice or B-cell deWcient MT mice, showed dramatically reduced virus titers in the salivary glands and blood of infected mice [8] . Moreover, when monoclonal antibodies were used in protection assays, it was found that protection from CMV infection correlates with aYnity to CMV antigens: the antibodies with the higher aYnity protected the mice much better than the antibodies with lower aYnity [9] . To better understand the role of antibodies and B cells in MCMV infection, Jonjic and co-workers investigated CMV infection in the MT mice that lack B cells. Using these mutant mice, it was possible to demonstrate that neither B cells nor antibodies are essential for the resolution of primary CMV infection [10] . Interestingly, it was found that reactivation from virus latency is the only situation where B cell or antibodies play a role, as virus reactivation results in higher virus titers in MT mice compared to control mice, presumably because virus spread and
University of Mainz, Obere-Zahlbacherstr. 63, 55131 Mainz, Germany e-mail: Waisman@uni-mainz.de dissemination is no longer blocked by antibodies [10] . As recurrent infection is thus apparently facilitated in MT mice, these mice were used to study the role of diVerent lymphocyte subsets in MCMV immune surveillance. MT mice were infected with MCMV, and after the virus became latent, T cells and NK cells were depleted using antibodies. As early as three days after lymphocyte depletion, virus recurrence became detectable [11] . Further it was found that T cells are more important than NK cells in MCMV immune surveillance, as for the virus to be activated in MT mice it was suYcient to delete CD4 + and CD8 + T cells [11] . Moreover, a recent work from the laboratories of Winkler and Mach [12] has shown that transfer of antigen experienced B cells, alone in mice that lack B and T cells (RAG deWcient mice) was suYcient for protection to MCMV. These Wndings show that B cells and antibodies play a critical role in control of MCMV latency and that T cells are critical to keep the virus latent in the absence of B cells.
B cell depletion and B cell-deWcient mice
How can we study the role of B cells in infections in general, or with a focus particularly on CMV infection? Over the last years, two main methods and mouse models were generated for such studies. The Wrst involves the in vivo deletion of B cells using monoclonal antibodies. The Wrst attempts were by using anti-IgM depleting antibodies [13] . These experiments led to 90-95% deletion of mature B cells, but did not result in plasma cell depletion. As a consequence, mice that have already developed a mature immune system were left with high levels of antibodies also after anti-IgM-mediated depletion, as plasma cells were shown to have a long lifespan [14] . Similarly, depleting antibodies directed to another B cell surface molecule, CD20, are currently used [15] . These antibodies deplete B cells more eYciently than anti-IgM antibodies, and importantly, can also model B cell depletion in humans, as the human anti-CD20 antibodies are already in clinical use in diVerent cancers [16, 17] . Nevertheless, also these antibodies do not reach 100% depletion of B cells, but rather 95%. Additionally, it is not possible to deplete plasma cells, which do not express the CD20 receptor.
In 1991, the group of Klaus Rajewsky introduced a new mouse model that contains a deletion in the genome that prevents the expression of IgM on the surface of developing B cells [18] . As a consequence, B cells did not receive the required signals for their development and the mice were devoid of these cells. These mice, termed MT, were used in many experiments to study how B cell deWciency aVects the immune response. In particular, the MT mice were used in diVerent infection models [19, 20] , including models of CMV infection as discussed above [8, 10, 11] . Because of the nature of the mutation introduced in the genome of MT mice, these mice were found to be leaky, especially when crossed to the BALB/c genetic background. As IgM and IgD constant regions ( and , respectively) are coded in the mouse on a bicistronic transcript, it is possible in rare cases for B cells to develop as IgD + , thus The second polyA site is located down stream of the membranal exons, and was not deleted. Therefore, this locus can code only for the mebranal-form of the constant region of the IgM antibody, and not the secreted form like the wild type locus bypassing the need for IgM in B cell development. These IgD + B cells are rare in MT mice [21] , but nevertheless can give rise to B cells that subsequently go through the process of class-switch recombination and diVerentiate to plasma cells that eventually Wll up the plasma cell compartment [21, 22] . A better model to study the role of B cells in B cell deWcient mice is the JHT mouse model (see Figs. 1, 2) . These mice harbor a deletion of the JH minigenes [23] , generated using the Cre-loxP system. They are truly devoid of B cells in all tested genetic backgrounds. Thus, the JHT strain is a more suitable model for studying immune responses in the absence of B cells. However, these mice also suVer from an inherent problem, namely their lack of B cells throughout the entirety of their development. It seems that B cells play a role in shaping the immune system, in particular in shaping the repertoire of CD4 + T cells [24] . It is therefore diYcult to draw reliable conclusions on the role of B cells during infection if the T cell responses are compromised.
New mouse models to study the role of B cells in infectious diseases
Diphtheria toxin (DT) is not toxic in mice when used in low concentrations, as mice do not express its high aYnity receptor. Jung and colleagues have shown that if dendritic cells (DCs) are made to express the simian diphtheria toxin receptor (DTR) in a transgenic mouse, these DCs can be ablated when mice are injected with DT [25] . We have recently constructed a new murine system where the simian DTR is expressed following Cre-mediated recombination [26] . This new mouse strain is termed iDTR, as the expression of DTR is induced by the Cre-recombinase. Using this system, we were able to demonstrate that following multiple injections with DT, more than 98% of the B cells were depleted in mice expressing Cre recombinase under the CD19 promoter (see Fig. 3, adapted from [26] ). The Crerecombinase is an enzyme that recognizes a speciWc sequence termed loxP. When this enzyme identiWes two of these sequences in the genome, it is able to remove the DNA Xanked by these loxP sites, and one of the loxP sites. The Cre/loxP system is a "genetic memory" system in that in every cell where Cre-recombinase was active in, like B cells in CD19-cre, DNA will stay recombined. In the case of the iDTR mice, this means that plasma cells, which are derived from CD19 + B cells but cease to express this receptor, do indeed still express DTR. Preliminary data from our laboratory indicates that also all B cells and B-cell derived cell types are depleted in CD19-cre/iDTR mice after administration of DT (F.D. and A.W., data not shown).
Thus, the iDTR mouse strain allows for the eYcient depletion of B cells. Another advantage it has over depletion with B-cell speciWc antibodies is the lack of immunity to DT in the mouse. We have shown that repeated injection of mice with DT, even together with an adjuvant, does not result in the development of neutralizing antibodies [26] . This Wnding together with the relatively low price of DT compared to antibodies as well as the ease of its usage, make the iDTR a favorable mouse model for B cell ablation. As the iDTR mice were done using embryonic stem cells of the C57BL/6 genetic background, they are available in this pure genetic background that facilitate the investigation of immune responses.
The JHT mouse model allows for the study of the role of B cells and antibodies in diVerent infectious diseases. What it does not allow for is the diVerentiation of the role of B cells versus secreted antibodies in these responses. For that, one needs a mouse strain in which B cells can develop, but are devoid of antibodies. For this purpose, we have generated the IgMi mouse strain [27] . As can be seen in Figs. 1  and 2 , we have generated a mouse strain where the polyA responsible for the secreted form of antibodies is deleted in the genome of the mice, allowing coding only of membrane immunoglobulin (the B cell receptor). The constant region coding for the heavy chain of IgM (termed C ) contains two polyA sites. The Wrst, which we deleted in the genome of the IgMi mice is essential for the maturation of the RNA that is transcribed to the secreted form of the IgM heavy chain (secreted IgM antibodies). The second polyA which we did not delete, is the one responsible for the maturation of the membrane-form of the IgM heavy chain (IgM B cell receptor). The resulting IgMi mice (which are available in 
